Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients

Open access
Absenger, G, Szkandera, J, Pichler, M, Stotz, M, Arminger, F, Weissmueller, M, Schaberl-Moser, R, Samonigg, H, Stojakovic, T, Gerger, A·2013·British Journal of Cancer

Abstract

BACKGROUND: Inflammation has a critical role in the pathogenesis and progression of cancer. Recently, the derived neutrophil to lymphocyte ratio (absolute count of neutrophils divided by the absolute white cell count minus the absolute count of neutrophils; dNLR) has been shown to influence clinical outcome in various cancer entities. In this study, we analysed the dNLR with clinical outcome in stage II and III colon cancer patients. METHODS: Three-hundred and seventy-two patients with stage II and III colon cancer were included in this retrospective study. Kaplan-Meier curves and multivariate Cox proportion analyses were calculated for time to recurrence (TTR) and overall survival (OS). RESULTS: In univariate analysis, the elevated preoperative dNLR was significantly associated with decreased TTR (hazard ratio (HR) 2.38, 95% confidence interval (CI) 1.57-3.6, P<0.001) and remained significant in multivariate analysis. Patients with dNLR >3 had a median TTR of 83 months, and patients with dNLR ≤ 3 showed a median TTR of 132 months. In OS analysis, a dNLR >2.2 was significantly associated with decreased OS in univariate (HR 1.85, 95% CI 1.11-3.08, P=0.018) and multivariate analysis. Patients with dNLR >2.2 showed a median OS of 121 months, and patients with dNLR ≤ 2.2 had a median OS of 147 months. CONCLUSION: The dNLR may be an independent prognostic marker for TTR and OS in patients with stage II and III colon cancer. Independent validation of our findings is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2013.346

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 225

Metadata

Authors
Absenger, G., Szkandera, J., Pichler, M., Stotz, M., Arminger, F., Weissmueller, M., Schaberl-Moser, R., Samonigg, H., Stojakovic, T., & Gerger, A.
Venue
British Journal of Cancer
Published
2013-07
Volume
109
Issue
2
Pages
395-400
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2070199947
Cited by
225
References
1
FWCI
10.28
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. https://app.cochat.ai/papers/10.1038/bjc.2013.346
The paper
Absenger, G., Szkandera, J., Pichler, M., Stotz, M., Arminger, F., Weissmueller, M., Schaberl-Moser, R., Samonigg, H., Stojakovic, T., & Gerger, A. (2013). A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. British Journal of Cancer. https://doi.org/10.1038/bjc.2013.346

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.